REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its …
MINNEAPOLIS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SPS Commerce, Inc. (NASDAQ: SPSC), a leader in retail cloud services, today announced that management will present at the Morgan Stanley Technology, Media & Telecom Conference on Thursday, March 7, 2024, …
CHICAGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events …
LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (NASDAQ: PTVE) today announced that its board of directors has approved the payment of a quarterly dividend of $0.10 per share of common stock. The dividend will be paid on March 29 …
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks’ digital channels, today announced that its fourth quarter ended December 31, 2023 financial results will be released on March 14, 2024, after …
LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in …
LYNNWOOD, Wash., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Zumiez Inc. (NASDAQ: ZUMZ) today announced it will report fiscal 2023 fourth quarter and full year results on Thursday, March 14, 2024, following the closing of regular stock market trading hours. The …
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the trial - - Initial topline results expected in mid-2024 – - …
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, …
Full year SaaS revenue of $161.0 million, representing 37% year-over-year growth Full year Total revenue of $271.8 million, representing 17% year-over-year growth Total ARR of $264.5 million, representing 23% year-over-year growth, 24% adjusted for FX …
Company Achieves Second Highest Fiscal Year Revenue in Company History Despite Restricted Supply of Smoothie Bottle Product Throughout Fiscal Year 2023 and National Carton Supply Shortage in Fourth Quarter 2023 Revenue of $8.1 Million and Gross Margins of …
Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company …
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and …
Fourth Quarter 2023 Financial Highlights: Total Net Revenues of $1,274 million for the fourth quarter of 2023 were down 14% compared to $1,476 million in the fourth quarter of 2022 and down 8% compared to $1,379 million in the third quarter of 2023. Net …
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move …
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 2024- -Upcoming Type-B Meeting with FDA in Q1 2024 to …
Gross profit increased by 55% to $18.2 million for the fourth quarter of 2023 Gross margin for the fourth quarter of 2023 increased to 87.3% from 68.0% last year Inuvo management to host conference call today at 4:15 PM ET LITTLE ROCK, Ark., Feb. 29, 2024 …
– Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively – – Long-term data from Phase 2b ENLIVEN trial demonstrated sustained benefits of …
Board of Directors Declared Total Dividends of $0.65 per Share for First Quarter 2024 Base Dividend of $0.43 and Supplemental Dividend of $0.22 Per Share EVANSTON, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” …
Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December 31, 2023; Reiterate anticipated cash runway into 2027 …
